Statistics on Medicines Consumption 2009
Total Page:16
File Type:pdf, Size:1020Kb
STATE AGENCY OF MEDICINES STATISTICS ON MEDICINES CONSUMPTION 2009 Riga, 2010 Author: State Agency of Medicines Prepared by: E. Gailite, A. Zake, A. Seilis Publisher – State Agency of Medicines © 2010 When using or quoting the data included in this issue, please indicate the source CONTENTS Introduction 4 Calculations 6 Results 7 Medicines consumption share according to consumer groups (% of total turnover - LVL) 9 TION 2009 Medicines consumption share according to consumer groups (% of number of packagings sold) 10 Market share according to sales to pharmacies (% of sales – LVL) 11 MP Market share according to sales to hospitals (% of sales – LVL) 12 U Market share according to sales to other medical establishments (% of sales – LVL) 13 S Market share according to sales to other wholesalers (% of sales – LVL) 14 Medicines consumption share according to dispensing status – prescription or ON C non-prescription medicines (% of total turnover – LVL) 15 Medicines consumption share according to dispensing status – prescription or non-prescription medicines (% of total turnover – LVL) through years 16 ES Medicines consumption share according to dispensing status – prescription or non-prescription medicines (% of number of packagings sold) 17 Medicines consumption share according to dispensing status – prescription or non-prescription medicines (DDD/1000 Latvian inhabitants/day) through years 18 DICIN Medicines consumption (DDD/1000 inhabitants/ day) 19 E Most marketable medicines (total consumption DDD/ 1000 inhabitants/ day) 42 The composition of the sales amount for medicines in 2009 according to the number of packagings sold by general type pharmacies 43 Manufacturers’ sale volumes according to medicines sold to pharmacies, hospitals, veterinary medicine ON M establishments and other health care centres (% of sale (LVL)) in 2009 48 S Medicines consumption by manufacturers (% of sale (LVL)) through years 49 Medicines consumption by manufacturers (turnover in LVL) through years 50 TIC Medicines consumption according to Marketing Authorisation Holders (turnover in LVL) in 2009 51 S Most marketed prescription medicines by DDD/1000 inhabitants/ day 52 TI Most marketed prescription medicines by turnover in LVL (international trade name) 53 A Most marketed prescription medicines by turnover in LVL (original trade name) 54 Most marketed non-prescription medicines by DDD/1000 inhabitants/ day 55 ST Most marketed non-prescription medicines by turnover in LVL (international trade name) 56 Most marketed non-prescription medicines by turnover in LVL (original trade name) 57 Medicines consumption by ATC groups (DDD/1000 inhabitants/ day in %) in 2009 58 Medicines consumption by ATC groups (DDD/1000 inhabitants/ day) through years 59 Medicines consumption by ATC groups (consumption (LVL)) in 2009* 60 Medicines consumption by ATC groups (consumption in LVL) through years * 61 Most marketed medicines of ATC 2nd level(DDD/1000 inhabitants/ day) 62 Most marketed medicines of ATC 3rd level (DDD/1000 inhabitants/ day) 63 2009 sales figures for the market of veterinary medicines 64 The most demanded veterinary medicines in 2009 after ATCvet level 5 (according to the number of packagings sold) 65 The most demanded antiinfectives for systemic use (according to the number of packagings sold) 66 Composition of the sales amount of ATCvet group QJ51RV01 (antibiotics and corticosteroids) veterinary medicines 67 Quarterly division of the sales amount of the most demanded antiinfectives for systemic use in 2009 (according to the number of packagings sold) 68 The most demanded veterinary medicines in 2009 according to the number of packagings sold (by original brand name) 69 STATE AGENCY OF MEDICINES 3 INTRODU C T I ON Statistics on medicines consumption is an integral part of the pharmacy industry compiling information on the medicines utilisation. Data on consumption are investigated by dividing medicines into groups according to their application basing of the ATC/DDD classification system. TION 2009 Anatomical Therapeutic Chemical (ATC) and Defined Daily Dose (DDD) system is an international MP standard for drug utilization studies recommended by the World Health Organisation (WHO). The purpose of the U ATC/DDD system is to serve as a tool for medicines utilization research in order to compare medicines consumption S between countries, regions as well as to see tendencies in medicines utilisation in different times and levels. ON Interest in medicines consumption since 1960-ies (time when they started to investigate C medicines consumption by dividing medicines into groups of their application) has increased significantly. The main objective of the ATC/DDD system it to use this as a tool for compiling ES statistical data with an aim to enhance a rational use of medicines. This systems has been used since 1970 when it was recognised as an appropriate tool for comparing data at national and international levels. Within the ATC classification system, the medicines are divided into different groups according to the organ or system on which they act and their chemical, DICIN pharmacological and therapeutic properties. Medicines are classified in groups at five different E levels. The classification of a substance in the ATC/DDD system is not a recommendation for use, nor does it imply any judgements about efficacy or relative efficacy of drugs and groups of ON M drugs. S (Reference: „Guidelines for ATC and DDD classification assignment” WHO Collaboratoring TIC Centre for Drug Statistics Methodology, Oslo 2006) S TI A ST STATE AGENCY OF MEDICINES 4 METHOD Medicines consumption statistics of the Republic of Latvia compiles data on human medicines used in 2005 to 2009. Data have been collected by compiling and analysing sales figures submitted by the wholesalers (in 2009 - 40 wholesalers) to the State Agency of Medicines TION 2009 (SAM). MP For a research and comparison purposes of a specific medicinal product the SAM uses U DDD figure allocated by the World Health Organisation Collaborating Centre for Drug Statistics S Methodology (hereinafter - WHO-Centre). The DDD is an assumed average maintenance dose per day for a drug used for its main indication in adults. It should be emphasised that the ON C defined daily dose is a unit of measurement and does not necessarily reflect the recommended or prescribed daily dose. ES The SAM uses „ATC Index with DDDs”, published by the WHO – Centre as a reference. WHO-Centre publishes changes within the ATC/DDD system once a year. The SAM uses the most recent version and on separate occasions it causes discrepancies for some medicinal products when comparing statistical data over years (for example, the DDD value for Simvastatin DICIN (C10AA01) was changed in 2009 from 15 mg (oral dose form) to 30 mg (oral dose form)) or E discrepancies in the data of an ATC subgroup (e.g., in 2009 the ATC code for Bupropion was changed from N07BA02 to N06AX12). ON M S TIC S TI A ST STATE AGENCY OF MEDICINES 5 CAL C ULAT I ONS The medicines consumptions statistics is measured using Defined Daily Dose (DDD). TION 2009 DDD is an average adult dose used for the main indication. For the statistical calculations at country level the SAM uses ATC codes allocated by the WHO-Centre and assigned DDDs, but MP for comparisons with statistical data of other countries the SAM uses a figure recommended by U the WHO-Centre – number of DDD units used in one day per 1000 inhabitants, as follows: S ON C Number of DDDs x 1000 365 x Number of inhabitants in Latvia ES For example, Gliclazidum consumption in 2009 is as follows: DDD Gliclazidum: 0,16 g DICIN E Total consumption: 245 733,24 g per year Number of inhabitants: 2 261 300 1. Total Gliclazidum consumption is expressed in DDDs applying the following formula: ON M S 245 733,24 g/ 0,16 g = 1 535 832,75 DDD 2. In order to calculate DDDs used in one day per 1000 inhabitants we place numbers in TIC the above formula: S TI A 1 535 832,75 x 1000 inhabitants/day = 1,86 DDD /1000 ST 365 x 2 261 300 The figure 1,86 DDD /1000 inhabitants/day shows that 2 inhabitants out of each 1000 Latvian inhabitants uses 1 therapeutical dose of Gliclazidum every day. However is should be noticed that DDD is a technical tool and it does not reflect a real daily dose. It is hard to assign DDD for medicines as the doses depend on indications, individuals and therapeutical practices. We should also take into consideration a fact that sales figures provided by the wholesalers do not reflect the real numbers of medicines used as medicines may be still in pharmacies or at homes. DDD is calculated per total number of inhabitants although medicines are used by patients of a specific age or sex. However even taking into consideration the above facts the DDD system is still a very appropriate tool for statistical researches. STATE AGENCY OF MEDICINES 6 RESULTS 2009 sales figures of medicines for human use* Thanks to wholesalers’ responsiveness the SAM and wholesalers have a successful cooperation resulting in providing data on medicines sales figures in Latvia. Data have been TION 2009 collected and compiled since 2001 on regular basis. Since 2005 information relating to sales MP figures has been compiled quarterly. U In order to evaluate the amount of medicines reaching a consumer all data analysis are S based on medicines consumption data reflecting the real situation – medicines reaching the next ON level within the sales chain. Medicines consumption data do not take into account information C if one wholesaler sells medicines to an another wholesaler, as in this case medicines are not provided to a consumer but stays where they are – within the wholesaler. ES Also information on consumer groups is analysed – we collect data from hospitals, clinics, pharmacies, rehabilitation establishments, specialised centres, emergency medicines centres, outpatient clinics and departments, doctor’s practices and different diagnostic laboratories and DICIN veterinary health care establishments (veterinary clinics).